NEW YORK (MarketWatch) -- Pfizer Inc. said early Tuesday its second-quarter proft came in at $2.47 billion, or 31 cents a share, compared to $2.26 billion, or 34 cents a share, in the year-ago period. On an adjusted basis, the pharmaceutical giant's earnings rose to $4.96 billion, or 62 cents a share, from $3.25 billion, or 48 cents a share, a year ago. Quarterly revenue jumped 58% to $17.3 billion, helped by a $5.4 billion boost from its Wyeth acquisition that was completed in October 2009. Pfizer beat by 10 cents the Wall Street estimate of 52 cents a share, according to a survey of analysts by FactSet Research. Analysts also estimated second-quarter revenue of $16.63 billion, and 2010 earnings of $2.17 a share. Specifically, revenue from the specialty care unit more than doubled to $3.77 billion thanks in part to sales of menopause treatment, Premarin. "Pfizer's more balanced global portfolio...and diversified products generated strong performance in a period of notable worldwide economic uncertainty," said Chief Executive Jeff Kindler in a statement. Looking ahead, the company expects to earn $2.10 to $2.20 a share on an adjusted-basis for the full year. Pfizer shares gained about 2.5% in premarket action.Pfizer's profit up with Wyeth acquisition
NEW YORK (MarketWatch) -- Pfizer Inc. said early Tuesday its second-quarter proft came in at $2.47 billion, or 31 cents a share, compared to $2.26 billion, or 34 cents a share, in the year-ago period. On an adjusted basis, the pharmaceutical giant's earnings rose to $4.96 billion, or 62 cents a share, from $3.25 billion, or 48 cents a share, a year ago. Quarterly revenue jumped 58% to $17.3 billion, helped by a $5.4 billion boost from its Wyeth acquisition that was completed in October 2009. Pfizer beat by 10 cents the Wall Street estimate of 52 cents a share, according to a survey of analysts by FactSet Research. Analysts also estimated second-quarter revenue of $16.63 billion, and 2010 earnings of $2.17 a share. Specifically, revenue from the specialty care unit more than doubled to $3.77 billion thanks in part to sales of menopause treatment, Premarin. "Pfizer's more balanced global portfolio...and diversified products generated strong performance in a period of notable worldwide economic uncertainty," said Chief Executive Jeff Kindler in a statement. Looking ahead, the company expects to earn $2.10 to $2.20 a share on an adjusted-basis for the full year. Pfizer shares gained about 2.5% in premarket action.
Suscribirse a:
Enviar comentarios (Atom)
1 comentario:
Pfizer gana un 9,4% más en el trimestre
El laboratorio farmacéutico estadounidense Pfizer obtuvo un beneficio neto de 2.475 millones de dólares (1.870 millones de euros) en el segundo trimestre del año, lo que supone una mejora del 9,4% respecto al mismo periodo de 2009, informó la empresa, que facturó un 57,7% más, hasta 17.327 millones de dólares (13.092 millones de euros). No obstante, en los seis primeros meses del ejercicio Pfizer obtuvo un beneficio neto de 4.501 millones de dólares (3.401 millones de euros), un 9,8% menos, mientras que sus ventas aumentaron un 56%, hasta 34.077 millones de dólares (25.749 millones de euros). Hemos reafirmado nuestras perspectivas financieras para 2010 y nuestros objetivos para 2012, apuntó el director financiero de la farmacéutica, Frank D'Amelio, quien espera que el beneficio por acción de Pfizer se sitúe en la parte alta de la horquilla de previsiones, mientras los gastos, por el contrario se situarían en la parte baja.
Publicar un comentario